Apollomics secures $10 million in private placement funding

Biotechnology company Apollomics Inc. said on Friday it raised $10 million in a private placement of equity securities, proceeds from which will be used to advance its late-stage oncology development programs and clinical trials.

The company, which focuses on developing treatments for solid tumors and hematologic malignancies, did not disclose the names of investors or the per-share price in the transaction. Private placements typically involve accredited investors and are not subject to the same regulatory disclosure requirements as public offerings.

Apollomics plans to allocate the funds toward advancing its lead drug candidates through Phase II and Phase III trials, as well as expanding its research and development capabilities. The company’s pipeline includes targeted therapies and antibody-drug conjugates aimed at addressing unmet medical needs in oncology.

The financing follows prior rounds that supported the company’s growth in both the U.S. and China, where it maintains a significant operational presence. Apollomics has not provided a timeline for the deployment of the new capital or specific milestones tied to the funding.

Private placements are a common financing tool for biotech firms, particularly those in early or mid-stage development, to extend cash runway without immediate dilution to public shareholders. The company’s shares are not publicly traded.

Apollomics did not respond to requests for comment on investor details or strategic priorities beyond the stated use of proceeds.